Timothy M. Cunningham
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Timothy M. Cunningham
Timothy M. Cunningham is recorded as CFO at Rein Therapeutics, Inc. (RNTX). Rein Therapeutics, Inc. reported in an 8-K filed May 16, 2024 that Timothy M. Cunningham was appointed principal financial officer and principal accounting officer, effective May 16, 2024. Rein Therapeutics, Inc. reported in an 8-K filed May 16, 2024 that Timothy M. Cunningham was appointed interim chief financial officer, effective May 16, 2024. The proxy statement of Rein Therapeutics, Inc. reports total compensation of $433,940 for Timothy M. Cunningham in fiscal 2025, including a base salary of $433,940. Disclosed compensation is on record for 2 fiscal years.
“In connection with his appointment, Mr. Cunningham will serve as the Company's principal financial officer and principal accounting officer, replacing Charles Garner in such roles following Mr. Garner's departure from the Company on May 15, 2024.”
“On May 15, 2024, the Board of Directors of Aileron Therapeutics, Inc. (the "Company") appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC ("Danforth"), as interim chief financial officer, effective as of May 16, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Rein Therapeutics, Inc. (RNTX)
SEC 8-K
Current2024-05-16–present
-
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Rein Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Brian Windsor CEO, COO, Board Member
- Brian Windsor, Ph.D. CEO, COO, Board Member
- Josef H. von Rickenbach Chairman, Board Member
- Charles Garner CFO
- Donald V. Dougherty CFO
- Manuel Aivado Chief Accounting Officer
- Alan A. Musso Board Member
- Manuel C. Alves-Aivado, M.D., Ph.D. Board Member
- Reinhard Ambros, Ph.D. Board Member
- Reinhard J. Ambros Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Rein Therapeutics, Inc. (RNTX) | Interim Chief Financial Officer | $433,940 | $433,940 |
| 2024 | Rein Therapeutics, Inc. (RNTX) | Interim Chief Financial Officer | $275,600 | $275,600 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.